Dr. Brahmer on Managing Immune-Related AEs in Lung Cancer

(1:29)

Dr. Brahmer Explains PD-1 and PD-L1

(1:43)

Dr. Brahmer on Distinguishing Between Immunotherapy Response and Cancer Growth

(1:16)

KMTV Omaha - Interview with Omaha native, Dr. Julie Brahmer

(4:16)

Dr. Brahmer on the Benefit of Immunotherapy in Metastatic NSCLC

(1:32)

Join Dr. Brahmer at the 20th Annual Winter Lung Cancer Conference

(1:31)

Replay of the Live Conversation with Dr. Barbara Natterson Horowitz

(1:5:46)

Immunotherapy for Lung Cancer: What Patients Need to Know, with Julie Brahmer

(1:52)

What Causes Chemobrain?

(17:32)

April 9, 2024 - Beshay Zordosky, MSc, PhD

(59:9)

PD-1, PD-L1 role in immune system inhibition

(6:8)

How is Immunotherapy Used to Fight Cancer? | Dana-Farber Cancer Institute | Science Illustrated

(2:44)

BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD

(22:44)

Immunotherapy - PD-1 and Beyond - Melanoma Education Symposium, Patrick Ott MD PhD

(34:37)

Cancer Immunotherapy - PD-1 and PD-L1

(4:)

Update on Immunotherapy for Glioblastoma - Robert Prins, Ph.D.

(11:50)

Dr. Brahmer on the Role of Immunotherapy in Metastatic NSCLC

(1:31)

Dr. Brahmer Discusses the Management of Adverse Events From Immunotherapy

(1:30)

Dr. Julie Brahmer named Meyerhoff Professor in Thoracic Oncology

(29:54)

Dr. Brahmer on 5-Year Follow-Up Data for Nivolumab in NSCLC

(1:18)

Copy of Dr. Brahmer on the Role of Immunotherapy in Metastatic NSCLC

(31)

Dr. Brahmer Discusses Frontline Single-Agent Pembrolizumab in Lung Cancer

(1:48)

Dr. Brahmer on Targeting Driver Mutations in NSCLC

(1:14)

Copy of Dr. Brahmer on Immunotherapy in Stage IV NSCLC

(19)

Dr. Brahmer on Immunotherapy Beyond PD-1/L1 in NSCLC

(1:15)

Dr. Brahmer Discusses Response to Immunotherapy

(1:25)

Dr. Brahmer Discusses the Future of Antibodies for Lung Cancer

(1:56)

Dr. Brahmer Discusses Tumor Vaccines for Lung Cancer

(2:3)

Dr. Brahmer Discusses the Outlook for Immunotherapies

(58)